ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01582672
Recruitment Status : Active, not recruiting
First Posted : April 23, 2012
Last Update Posted : June 7, 2017
Sponsor:
Information provided by (Responsible Party):
Argos Therapeutics

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : December 2017
  Estimated Study Completion Date : April 2018